Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium Kit
Product Images NDC 68180-894

18 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium (NDC 68180-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-01 (F5347764 C224 4ba9 B57a 90a228f1ee07 01)

Image-01 (F5347764 C224 4ba9 B57a 90a228f1ee07 01)
A forest plot chart showing hazard ratios, rate ratios, and odds ratios from multiple studies labeled as prospective cohort studies, retrospective cohort studies, case-control studies, and non-fatal idiopathic cases only. The chart displays points with horizontal confidence intervals plotted on a logarithmic scale ranging from 0.1 to 10, representing the relative risk or association magnitude for each study.*
FDA Label Image

Image-02 (F5347764 C224 4ba9 B57a 90a228f1ee07 02)

Image-02 (F5347764 C224 4ba9 B57a 90a228f1ee07 02)
A horizontal bar chart displaying the number of women with a blood clot per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC user, COC-User, Pregnancy, and Postpartum (12 weeks only). The chart shows ranges for each group, with the highest range in the postpartum group (40 to 65) and the lowest in non-pregnant non-COC users (1 to 5). The pregnancy data includes a note about model assumptions related to pregnancy duration.*
FDA Label Image

Image (F5347764 C224 4ba9 B57a 90a228f1ee07 03)

Image (F5347764 C224 4ba9 B57a 90a228f1ee07 03)
This plot shows a forest chart comparing effect estimates for "Ever COC vs. Never COC Use" and "Current COC Use vs. Never-Use" from multiple studies. The x-axis represents the effect estimate ranging approximately from -1.5 to 2.0. Study-specific odds ratios (OR), relative risk (RR), and hazard ratios (HR) with confidence intervals are plotted as points with horizontal lines, showing variable effects and CIs across listed cohort and register studies.*
FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 2)

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 2)
Chemical structure of drospirenone depicted as a complex steroidal framework with multiple rings and functional groups, including ketone and lactone moieties.*
FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 3)

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 3)
Chemical structure of the active ingredient, likely related to drospirenone or ethinyl estradiol, displayed as a molecular diagram showing its atomic connectivity and bond arrangement.*
FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 4)

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 4)
Chemical structure of levomefolate calcium, showing its molecular connectivity and arrangement. The image is a structural diagram depicting atoms and bonds characteristic of this active ingredient.*
FDA Label Image

Image-03 (F5347764 C224 4ba9 B57a 90a228f1ee07 04)

Image-03 (F5347764 C224 4ba9 B57a 90a228f1ee07 04)
A line graph comparing plasma folate levels (mmol/L) over 24 weeks between two groups: YAZ + levomefolate calcium (N=196) and YAZ alone (N=66). The graph shows time in weeks on the x-axis and plasma folate concentration on the y-axis, with data points and error bars illustrating trends and variability for each group.*
FDA Label Image

Image (F5347764 C224 4ba9 B57a 90a228f1ee07 05)

Image (F5347764 C224 4ba9 B57a 90a228f1ee07 05)
A line graph showing RBC folates (nmol/L) levels over 24 weeks of treatment comparing YAZ (drospirenone, ethinyl estradiol) alone and YAZ plus levomefolate calcium. The x-axis represents time in weeks, with pre-treatment and 0, 4, 8, 12, 16, 20, and 24 week points. The y-axis shows RBC folates concentration from 0 to 2000 nmol/L. The graph indicates an increase in RBC folates with YAZ plus levomefolate calcium compared to YAZ alone, with error bars representing variability.*
FDA Label Image

Image (F5347764 C224 4ba9 B57a 90a228f1ee07 06)

Image (F5347764 C224 4ba9 B57a 90a228f1ee07 06)
A line chart showing plasma folates levels (nmol/L) over a 44-week period for a group treated with Yasmin plus levometafolate calcium (N=75). The x-axis represents time in weeks, divided into pre-treatment, treatment, and elimination phases, while the y-axis shows plasma folates concentration. Data points include error bars indicating variability.*
FDA Label Image

Image-06 (F5347764 C224 4ba9 B57a 90a228f1ee07 07)

Image-06 (F5347764 C224 4ba9 B57a 90a228f1ee07 07)
A line graph showing red blood cell (RBC) folate levels (nmol/L) over time in weeks for subjects treated with Yasmin + levomefolate calcium. The x-axis represents time from pre-treatment through treatment and elimination phases, while the y-axis shows RBC folate concentration. Data points include error bars indicating variability.*
FDA Label Image

Image Trade Mark (F5347764 C224 4ba9 B57a 90a228f1ee07 08)

FDA Label Image

Image-07 (F5347764 C224 4ba9 B57a 90a228f1ee07 09)

Image-07 (F5347764 C224 4ba9 B57a 90a228f1ee07 09)
An illustration showing a vertical scale of pregnancy frequency per 100 women per year from fewer to more pregnancies. It categorizes contraceptive methods by their association with pregnancy rates, with implants, injections, intrauterine devices, and sterilization linked to fewer pregnancies; birth control pills, skin patch, and vaginal ring with hormones slightly more; condoms and diaphragms further down; no sex during fertile days, spermicide, and withdrawal even lower effectiveness; and no birth control linked to the most pregnancies.*
FDA Label Image

Figure-08 (F5347764 C224 4ba9 B57a 90a228f1ee07 10)

Figure-08 (F5347764 C224 4ba9 B57a 90a228f1ee07 10)
An instruction diagram for weekly pill intake showing a 4-week cycle with days labeled Sunday through Saturday. It advises 'Day 1 starters' to place the day label strip starting with the first day of their period, with arrows indicating the daily sequence for taking the medication.*
FDA Label Image

Image-09 (F5347764 C224 4ba9 B57a 90a228f1ee07 11)

Image-09 (F5347764 C224 4ba9 B57a 90a228f1ee07 11)
A horizontal bar chart comparing the number of women with a blood clot per 10,000 woman years across four groups: Non-Pregnant Non-COC User, COC User, Pregnancy, and Postpartum (12 weeks only). The chart shows increasing blood clot risk from Non-Pregnant Non-COC User to Postpartum, with exact ranges indicated for each group.*
FDA Label Image

Image Trade Mark (F5347764 C224 4ba9 B57a 90a228f1ee07 12)

FDA Label Image

Image-10 (F5347764 C224 4ba9 B57a 90a228f1ee07 13)

Image-10 (F5347764 C224 4ba9 B57a 90a228f1ee07 13)
Packaging label for Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg. The label indicates 3 blisters of 28 tablets each and is distributed by Lupin Pharmaceuticals, Inc. The design includes barcodes and regulatory information. The product is marked Rx only and notes that it does not protect against HIV infection or other sexually transmitted diseases.*
FDA Label Image

Image-11 (F5347764 C224 4ba9 B57a 90a228f1ee07 14)

Image-11 (F5347764 C224 4ba9 B57a 90a228f1ee07 14)
Label for DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM tablets by Lupin Pharmaceuticals, Inc. The label specifies 3 mg/0.02 mg/0.451 mg and 0.451 mg tablet strengths. It indicates Rx only status and that the package contains 1 blister of 28 tablets. Manufacturer and distributor information is also displayed along with regulatory warnings and a website URL.*
FDA Label Image

Image-12 (F5347764 C224 4ba9 B57a 90a228f1ee07 15)

Image-12 (F5347764 C224 4ba9 B57a 90a228f1ee07 15)
Label for Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, containing 3 mg/0.02 mg/0.451 mg and 0.451 mg respectively. The label indicates storage instructions and includes manufacturer Lupin Limited and distributor Lupin Pharmaceuticals, Inc. The label also features a barcode, lot number, and expiration date area, along with a reminder for monthly self breast exams.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.